Business
Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
- ONGENTYS, the First and Only FDA-Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"- ONGENTYS, the First and Only FDA-Approved Once-Daily COMT Inhibitor, Decreases \"Off\" Time and Increases \"On\" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa\n - FDA Approval of ONGENTYS Supported by Data from 38 Clinical Studies, Including Two Multinational Phase III Clinical Studies (BIPARK-1 and BIPARK-2), with More Than 1,000 Parkinson's Disease Patients Treated with ONGENTYS\n\n\nSAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that 50 mg capsules of ONGENTYS® (opicapone), the first and only FDA-approved once-daily catechol-O-methyltransferase (COMT) inhibitor, are now available by prescription in the United States. ONGENTYS was approved by the U.S. Food and Drug Administration (FDA) on April 24, 2020, as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing \"off\" episodes. \nExperience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8773451-neurocrine-biosciences-ongentys-now-available/ \nParkinson's disease is the second most common neurodegenerative disorder in the United States after Alzheimer's disease. About one million Americans have Parkinson's disease and each year, an estimated 50,000 people in the United States are newly diagnosed with this chronic, progressive and debilitating neurodegenerative disorder.\n\"ONGENTYS is a new treatment option that decreases 'off' time, the period of time during the day when Parkinson's disease symptoms are bothersome, and increases 'on' time without troublesome dyskinesia, the period of time during the day when Parkinson's disease symptoms are better controlled,\" said Rebecca Gilbert, M.D., Ph.D., Vice President and Chief Scientific Officer of the American Parkinson Disease Association. \"The approval of ONGENTYS is welcome news to people with Parkinson's disease who are looking for additional medication possibilities to help control the often difficult symptoms of the disease that negatively impact their lives.\"\nONGENTYS is an oral, selective COMT inhibitor that helps block the COMT enzyme that breaks down levodopa, the gold standard therapy for controlling motor symptoms in patients with Parkinson's disease. ONGENTYS helps protect levodopa by reducing its breakdown in the bloodstream, making more levodopa available to ...